ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3

Isabella Lin,Zain Awamleh,Mili Sinvhal,Andrew Wan,Leroy Bondhus,Angela Wei,Bianca E. Russell,Rosanna Weksberg,Valerie A. Arboleda
DOI: https://doi.org/10.1186/s12920-024-02039-7
2024-11-30
BMC Medical Genomics
Abstract:Rare variants in epigenes (a.k.a. chromatin modifiers), a class of genes that control epigenetic regulation, are commonly identified in both pediatric neurodevelopmental syndromes and as somatic variants in cancer. However, little is known about the extent of the shared disruption of signaling pathways by the same epigene across different diseases. To address this, we study an epigene, Additional Sex Combs-like 1 ( ASXL1 ), where truncating heterozygous variants cause Bohring-Opitz syndrome (BOS, OMIM #605039), a germline neurodevelopmental disorder, while somatic variants are driver events in acute myeloid leukemia (AML). No BOS patients have been reported to have AML.
genetics & heredity
What problem does this paper attempt to address?